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The efficacy of voriconazole is potentially compromised by considerable pharmacokinetic variability. There are increasing in-
sights into voriconazole concentrations that are safe and effective for treatment of invasive fungal infections. Therapeutic drug
monitoring is increasingly advocated. Software to aid in the individualization of dosing would be an extremely useful clinical
tool. We developed software to enable the individualization of voriconazole dosing to attain predefined serum concentration
targets. The process of individualized voriconazole therapy was based on concepts of Bayesian stochastic adaptive control. Mul-
tiple-model dosage design with feedback control was used to calculate dosages that achieved desired concentration targets with
maximum precision. The performance of the software programwas assessed using the data from 10 recipients of an allogeneic
hematopoietic stem cell transplant (HSCT) receiving intravenous (i.v.) voriconazole. The programwas able to model the plasma
concentrations with a high level of precision, despite the wide range of concentration trajectories and interindividual pharmaco-
kinetic variability. The voriconazole concentrations predicted after the last dosages were largely concordant with those actually
measured. Simulations provided an illustration of the way in which the software can be used to adjust dosages of patients falling
outside desired concentration targets. This software appears to be an extremely useful tool to further optimize voriconazole
therapy and aid in therapeutic drug monitoring. Further prospective studies are now required to define the utility of the control-
ler in daily clinical practice.
Voriconazole is a second-generation triazole that is a first-lineagent for the treatment of invasive aspergillosis, invasive can-
didiasis, and a number of other opportunistic fungal pathogens
(1–3). Exposure-response and exposure-toxicity relationships are
increasingly well described in experimental and clinical contexts
(4–6). A trough concentration of 1 mg/liter is associated with
improved clinical outcomes and survival in adults and children
(7–10). Furthermore, a trough concentration of4.5 to 6mg/liter
is associated with an increased risk of both hepatotoxicity and
central nervous system toxicity (8, 9, 11). Therapeutic drug mon-
itoring to enable dosage adjustment to achieve these drug expo-
sure targets is increasingly advocated.
The pharmacokinetics (PK) of voriconazole are complicated.
Drug exposure is highly variable, and concentrations typically
vary approximately 100-fold even in healthy volunteers (12). Lit-
tle of this variability is explained by directly measurable and clin-
ically relevant covariates, such as weight or the CYP2C19 geno-
type. Furthermore, the pharmacokinetic behavior of voriconazole
is nonlinear (i.e., Michaelis-Menten) as a consequence of satura-
ble clearance mechanisms. At increasing concentrations, there-
fore, elimination of drug is limited to a constant amount per unit
of time, rather than a constant fraction of the concentration in
serum. For some patients, this results in a disproportionate in-
crease in drug exposure following dosage escalation. These prop-
erties pose a significant challenge to the real-time adjustment of
voriconazole dosages for critically ill patients to achieve prespeci-
fied drug exposure targets.
“Stochastic control” refers to the control of dynamic systems
whose underlying properties can only be estimated. Concepts of
stochastic control are ubiquitous and established in many engi-
neering processes and problems, such as flight control and rocket
telemetry. These ideas can also be applied to clinical pharmacol-
ogy. In this regard, the pharmacokinetic behavior of voriconazole
in an individual patient is a “dynamic system” whose properties,
such as clearance, are inferred from measured drug concentra-
tions. Here we describe the conceptual foundation that is required
for the stochastic control of plasma voriconazole concentrations
in critically ill immunocompromised patients. We describe the
development of software that is required for this process and il-
lustrate how this software can be used.
(This work was presented in part at the 22nd European Con-
gress of Clinical Microbiology and Infectious Diseases [ECC-
MID], London, United Kingdom, 2012.)
MATERIALS AND METHODS
Conceptual underpinning and construction of the controller. The con-
troller was based on concepts and software originally developed by the
University of Southern California Laboratory for Applied Pharmacoki-
netics (LAPK) (http://www.lapk.org). The multiple-model design and
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stochastic control of dosage regimens were initially described nearly 20
years ago (13) and have been applied to compounds such as vancomycin
(14) and to antiretroviral therapy for HIV infection (15). This software,
now called RightDose, can be used to individualize drug therapy. Right-
Dose is menu driven, runs under Windows operating systems, and em-
ploys a relatively simple graphical user interface. Models for many com-
monly monitored drugs exist in RightDose, but they are limited to
straightforward pharmacokinetic systems with solutions that can be esti-
mated algebraically. However, progressive developments in the algo-
rithms for adaptive control have recently enabled this same control pro-
cess to be applied tomuchmore complexmodels for compounds, such as
voriconazole, which require a differential equation solver to estimate an
individual patient’s pharmacokinetic parameter values.
RightDose currently exists only as an “engine” of Fortran files that
must be compiled in a terminal (DOS) window. Five of the engine files are
fixed, but the sixth file is a Fortran file that contains the mathematical
equations defining the structuralmodel of the drug to be controlled (vori-
conazole in this case). Estimating the values of the parameters in these
equations for an individual patient enables calculation of the plasma vori-
conazole concentration at any time after a given voriconazole dose, which
in turn permits calculation of the optimal dose that achieves specified
target plasma concentrations with maximum precision and accuracy. We
used a free-access G95 Fortran compiler (http://ftp.g95.org/) to compile
the six files into an executable software program, which was then run
within a DOS window. To distinguish this program from RightDose, we
will refer to it as “rightdose.exe” throughout this article.
Once executed, to calculate the optimal voriconazole dose for a given
patient, rightdose.exe required the following three input files: (i) a “pop-
ulation prior” distribution of voriconazole pharmacokinetic model pa-
rameter values obtained from a previous study of patients receiving vori-
conazole, which is described in more detail in the next section, (ii) the
patient’s history of voriconazole dosages and measured plasma concen-
trations, and (iii) the future concentration targets, the time(s) atwhich the
concentration target(s) should be achieved, and an initial estimate of the
dosage regimen to achieve the target(s) most precisely.
Building the population prior for voriconazole. In order to control
plasma voriconazole concentrations in an individual patient, it was nec-
essary to have an idea about the general distribution of values for each
parameter in the equations that define voriconazole pharmacokinetic be-
havior in adult patients. This is known as a “population prior” distribu-
tion of parameter values, and it is ideally described using data from richly
sampled participants in carefully conducted phase I-III clinical studies.
We constructed our voriconazole population prior using data from the
samples of 64 adults (21 healthy volunteers and 43 patients) who had been
enrolled in phase I and III clinical trials of voriconazole (12). The 21
healthy volunteers consisted of 14 patients who had received voriconazole
at 6mg/kg of bodyweight intravenously (i.v.) for two dosages, 3mg/kg i.v.
every 12 h (Q12h) for 1 week, and then 200 mg Q12h orally thereafter.
Following a washout period, these same patients had received 6mg/kg i.v.
for two dosages, 5 mg/kg Q12h i.v. for 1 week, and then 400 mg Q12h
orally thereafter. A second cohort of healthy volunteers had received 6
mg/kg i.v. for two dosages, 4 mg/kg i.v. Q12h, and then 300 mg orally
Q12h thereafter. Intensive sampling of these patients yielded a rich data
set. Trough concentrations had been obtained at the end of days 1 to 7,
with 13 samples throughout the dosing interval at the end of the first and
second weeks. The pharmacokinetic data were combined with the sparse
data from another 43 patients who had been enrolled in a phase III clinical
trial. Voriconazole was measured using a well-validated high-perfor-
mance liquid chromatography (HPLC) assay with a limit of detection of
0.01 mg/liter as described in a recent publication (12).
The mathematical structural model for voriconazole consisted of a
series of equations that defined absorption into a central compartment
after a delay, a peripheral compartment with distribution of drug to and
from the central compartment, andMichaelis-Menten saturable elimina-
tion from the central compartment, which made it necessary to use dif-
ferential equation solvers to estimate the population prior distribution of
parameter values from the study data. This was achieved using the non-
parametric population pharmacokinetic software program Big NPAG
(now embedded in the Pmetrics package, available from http://www.lapk
.org). We have recently published this population model and the prior
parameter value distributions (5). We chose the nonlinear Michaelis-
Menten model over a simpler linear pharmacokinetic model as recently
described (9) tomore adequately fit a wider range of dosage regimens and
patients.Nonlinear pharmacokinetics for voriconazole are invariably seen
with higher voriconazole doses, which then require the use of a structural
pharmacokinetic model with saturable clearance to adequately describe
the data (as was the case in the model used to construct the controller).
Importantly, however, such amodel can still describe patients whose vori-
conazole concentration falls at a constant fraction per hour (i.e., patients
with seemingly linear PK). In this case, the patient’s estimate forKmwill be
significantly higher than for that those patients who exhibit typical non-
linear PK. Similar to any drug with Michaelis-Menten behavior, the lin-
earity or nonlinearity of voriconazole PK in the literature and in individ-
ual patients is a function of the dose and resulting plasma concentrations,
relative to the patient’s Km parameter value.
The nonparametric population prior for voriconazole is a collection of
discrete support points. Each support point is a vector, comprising a value
for each parameter in the structural model equations plus the probability
of those values to describe voriconazole pharmacokinetic behavior in the
study population. The parameters in the structural model were the fol-
lowing: Ka, rate constant of voriconazole absorption from the gut to the
central compartment (h1); F, fraction of oral voriconazole absorbed
with respect to intravenous administration, i.e., bioavailability (no units);
lag, delay in absorption (h); Vc, volume of the central compartment (li-
ters);Vmax, the maximum rate of elimination by metabolism (mg/h); Km,
the serum concentration of voriconazole at which metabolism is half-
maximal (mg/liter); Kcp, rate constant of voriconazole distribution from
the central compartment to the peripheral compartment (h1); and Kpc,
rate constant of voriconazole distribution from the peripheral compart-
ment to the central compartment (h1).
The probabilities of all the support points add up to unity. The better
a given support point describes the behavior of voriconazole in a popula-
tion, the higher its associated probability. At most, there can be the same
number of support points in the joint density as study patients (64 in this
case). However, fewer support points are typical and reflect patients who
are similar enough relative to noise and model misspecification as to be
described by the same set of pharmacokinetic parameter values. In this
case, 42 support points were calculated from the original study population
of 64 patients receiving voriconazole (12).
General process of calculating the optimal voriconazole dose for an
individual patient. The nonparametric population prior serves as the
basis formultiple-model stochastic control for each newpatient forwhom
voriconazole therapy needs to be individualized. For a patient who has
already been receiving voriconazole and has measured plasma concentra-
tions, the procedure is as follows. (i) Update the prior probabilities of each
point to new “Bayesian posterior” probabilities based on the ability of
each support point to describe the patient’s measured voriconazole con-
centrations given the dosing history. (ii) Define a plasma voriconazole
target, such as a concentration of 1 mg/liter 12 h after the most recent
dose. (iii) Calculate the voriconazole dose that minimizes the weighted
squared error between the calculated concentration from the parameter
values of each point in the Bayesian posterior and the target.
Steps i and iii are accomplished by the rightdose.exe program with
appropriate patient data and model equation files, and step ii requires
consideration from the user. For patients who are initiating voriconazole
therapy (i.e., have no previous dosing or concentration data), step i is
skipped, and step iii is carried out using the full population prior distri-
bution.
The number of support points in the Bayesian posterior distribution
for an individual patient (step i above) is typically smaller than that in the
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prior distribution obtained from a larger population of patients and may
be as few as one. This is because many of the support points in the popu-
lation prior, which capture much of the pharmacokinetic variability of
voriconazole in adult patients, are unlikely to describe the new patient’s
observed voriconazole concentrations. Rather, an individual patient tends
to be described by a discrete subset of support points. Each of the support
points in the Bayesian posterior distribution for the new patient is, in
effect, one of the multiple pharmacokinetic models for that patient, each
weighted by its Bayesian posterior probability. Those support points that
describe the patient well have a higher probability, whereas those support
points that do less well have a lower associated probability. In this way, the
pharmacokinetic behavior of voriconazole in the individual patient can be
estimated using information that has been obtained from a broader pop-
ulation of patients, even with sparse or erratic samples. This Bayesian
posterior distribution for the individual patient forms the basis for sto-
chastic control of the voriconazole plasma concentrations using the dos-
age as the means of control.
The next step (step ii above) in the process of dosage individualization
is that the user must define the desired concentration target, the time in
the future that target must be achieved, and the schedule of drug admin-
istration. The user must also provide a best guess for the likely dosage,
which provides a reference point from which the estimation process be-
gins. The multiple-model algorithm then calculates the dosage that min-
imizes the weighted sum of squared differences between the desired target
concentration(s) and those that are calculated from each point in the
Bayesian posterior (step iii above). Less-probable support points contrib-
ute proportionally less than highly probable points to the calculated dos-
age that matches the desired concentration target with maximum preci-
sion and accuracy.
Testing the voriconazole controller. The performance of our vori-
conazole controller was assessed using the pharmacokinetic data derived
from 10 hematopoietic stem cell transplant (HSCT) recipients who had
received a standard regimen of voriconazole of 6 mg/kg Q12h i.v. for two
dosages followed by 4 mg/kg Q12h i.v. for 2 weeks; the results have been
previously published (16). Briefly, these patients were 18 to 65 years old
andweighed 66 to 100 kg. Therewas no clinical evidence of invasive fungal
infection. Voriconazole was commenced 1 week prior to transplantation
and continued for 14 days.
These patients were not included in the original 64 patients used to
construct the population prior (those patients are described in reference
12). Concentrations of voriconazole in plasma were measured using
HPLCwith a dynamic range for the assay of 0.1 to 10mg/liter, as described
in the original publication (16). The use of additional pharmacokinetic
data contained in previous publications for validation of the controller
(see, for example, data contained within references 7 and 10) was not
possible because the vast majority of these patients did not have enough
data points to simultaneously estimate pharmacokinetics and assess the
performance of the controller.
All voriconazole dosages and concentrations available from the HSCT
cohort were used, with the exception of the last dose and the single plasma
concentrationmeasured 12 h after that dose, which had been obtained 336
h after the first voriconazole dose. This data set constituted the past expe-
rience of each individual patient with voriconazole and allowed the phar-
macokinetics of each of the HSCT recipients to be estimated, using the
population prior obtained from the original voriconazole population
pharmacokinetic model (see step i in the section above) (12). The last
measured observation (i.e., voriconazole concentration), which was ob-
tained 12 h postdose, was used as the concentration target to plan the
future regimen (step ii). The dosage that was calculated by the controller
(step iii) was compared with the dosage that was actually given to the
patient. A plot of the observed-versus-predicted dosages was then con-
structed.
Simulations to demonstrate potential utility of the controller under
realistic conditions. We used rightdose.exe to illustrate its potential use
for a patient with trough concentrations of1 mg/liter and at increased
risk of concentration-dependent therapeutic failure. For this exercise, we
could have chosen any target concentration deemed important by a treat-
ing clinician (e.g., a trough concentration of 2 mg/liter). The simulated
patient received the standard (currently licensed) regimen on day 1 (6
mg/kg i.v. Q12 h, with drug infused over a 1-h period). We set the con-
centrations obtained 12 h after the first dose to be1 mg/liter. We used
rightdose.exe to calculate concentration-time out to 120 h after initiation
of voriconazole when a dose adjustment was made at 24 h based on the
“measured” drug concentrations or when the original (licensed) dose was
continued. The dose adjustment was not implemented until 24 h (i.e., the
third dose) to more realistically simulate the time required to transport
the specimen to the laboratory, measure concentrations of voriconazole
in plasma using an established analytical method (e.g., HPLC or mass
spectroscopy), and communicate the results back to the clinician for cal-
culation of a future regimen.
RESULTS
The observed data for each of the 10HSCT recipients were readily
described using each patient’s Bayesian posterior pharmacoki-
netic parameter values (Fig. 1). A linear regression of the ob-
served-versus-predicted data that were pooled for each individual
patient is shown in Fig. 2. The regression line was given by the
following: predicted concentration  0.086  (1.05  observed
concentration), with a coefficient of determination (r2) of 0.86.
Validation of performance of the controller. In the majority
of cases, there was close agreement between the voriconazole dose
calculated by the controller to optimally achieve the last observed
serum concentration and the actual dose that had been adminis-
tered (Fig. 3). Notably, there were twoHSCT recipients for whom
the controller predicted significantly more drug than was actually
administered. Inspection of the raw data from HSCT recipients 1
and 9 (Fig. 1) shows that the last data points that served as the
therapeutic targets for these two patients were notably different
from the predicted profiles in comparison to the other patients
(i.e., this was a problem with the data, not the performance of the
controller). The predicted dosage was not affected by the initial
guess for the dosage provided by the user (i.e., the same estimate
for the dosage was provided by the software regardless of whether
a realistic initial guess (e.g., 300 mg) or a completely unrealistic
initial guess (e.g., 1 mg) was made.
Simulations to demonstrate potential utility of the control-
ler under realistic conditions.The potential utility of the control-
ler is illustrated in Fig. 4, which depicts a typical patient for whom
the standard voriconazole regimen immediately results in a
trough concentration significantly lower than the target of 1 mg/
liter. Adjusting the dose to 10 mg/kg Q12h i.v. at 24 h rapidly
corrects the plasma profile and achieves therapeutic trough con-
centrations of 1 mg/liter. Prolongation of the infusion from 1 to 4
h resulted in the same trough concentration, but a significantly
lower peak concentration.
DISCUSSION
Although control theory has a long and robust history in engineer-
ing, it has not beenwidely applied or practiced in clinicalmedicine
or pharmacology. However, it can and should be embraced, since
the necessary computational and analytical expertise to control
highly variable and inherently unpredictable systems is available.
The control of variable systems (patients) whose outcomes are
dependent on achieving rapid and optimally precise control is an
urgent health care need and is central to current notions of per-
sonalized pharmacotherapy.
Hope et al.
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FIG 1 The fit of the voriconazole population pharmacokinetic model to serum concentrations obtained from 10 hematopoietic stem cell transplant recipients.
The solid squares are the raw serum data, and the solid line is the mean weighted prediction of the model fitted to the data. All patients received a standard i.v.
regimen of 6 mg/kg i.v. for two dosages, followed by 4 mg/kg i.v. every 12 h.
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Voriconazole is a fascinating agent. The structural modifica-
tions from fluconazole that extend the spectrum of activity from
Candida spp. tomedically important molds have been engineered
at a cost of less-predictable pharmacokinetics (17). Voriconazole
is an ideal candidate for therapeutic drug monitoring for the fol-
lowing reasons: (i) there are well-established drug exposure-effect
and drug exposure-toxicity relationships (7, 8, 10); (ii) there is
evidence that therapeutic drug monitoring may lead to improved
therapeutic outcomes (8, 18); and (iii) voriconazole exhibits sig-
nificant interpatient variability with classical nonlinear pharma-
cokinetics (12). While therapeutic drug monitoring may be a de-
sirable adjunct to the routine use of voriconazole, at this time
there are no algorithms that can be used to adjust the regimen to
attain predefined serumconcentration targets in an optimally pre-
cise manner. The multiple-model design with stochastic control
described in this study is a way in which this can now be achieved.
The process of real-time dosage adjustment (adaptive control)
begins with a population prior pharmacokinetic model. A popu-
lation prior model summarizes and stores past experiences with a
drug when administered to a population of interest. One of the
issues with voriconazole has been difficulty in constructing pop-
ulation pharmacokineticmodels. In order to describe the extent of
nonlinear pharmacokinetics that is characteristic of voriconazole,
a range of dosagesmust be studied to enable a rigorous estimate of
theKm-Vmax pair that jointly describes nonlinear,Michaelis-Men-
FIG 2 The observed-versus-predicted values for the 10 individual patients
shown in Fig. 1. The dotted line is the line of identity (observed predicted).
The solid line is the regression line fitted to pooled data and is given by the
following: predicted concentration  0.086  (1.05  observed concentra-
tion) (r2  0.86). Patient numbers and symbols are shown at the top of the
figure.
FIG 3 Predictive performance of the controller. All but the last concentration from the 10 patients shown in Fig. 1 were used to estimate each individual’s
pharmacokinetics. The controllerwas used to calculate the dosage to achieve the last observed concentration. This dosagewas then comparedwith the dosage that
was actually administered. The solid line is the line of identity (i.e., predicted dose actual dose). Two dosages recommended by the controller were significantly
different from those that were ultimately administered. In both cases, this is a result of outlying measurements at 336 h for patient 1 and patient 9.
Hope et al.
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ten clearance.While a range of i.v. and oral regimens were studied
in phase I studies, a single fixed regimen was used in phase II and
III trials (1, 19). This limitation has been an obstacle for the de-
velopment of population pharmacokinetic models of infected
adult patients. Recently, this limitation was circumvented by co-
modeling data from healthy volunteers with those from patients
(12). While such an approach is not perfect, it at least provides a
foundation for further pharmacokinetic studies and has enabled
the construction of this stochastic controller.
We used a nonparametric approach throughout. For the pur-
poses of feedback control, a fully parametric approach has the
limitation of allowing only one possible value for each parameter
and therefore does not allow for the possibility that themodel does
not fully describe the patient in question. Because parametric
models are a single-model approach, they have no means to eval-
uate and optimize the expected precision with which a dosage
regimen will achieve a desired target. This fact is well described by
the separation principle (20), which states that whenever a system
is controlled by first obtaining single point parameter estimates
(as in a parametric model) and then controlled using these single
point values, the result is suboptimal because there is no perfor-
mance index to optimize the outcome.
This multiple-model stochastic controller represents a first
critical step in the process of further optimizing voriconazole ther-
apy for the treatment of critically ill immunocompromised pa-
tients. Clearly there are a number of challenges that must still be
overcome before this software can be used in the routine care of
patients. The first challenge relates to the nonlinear pharmacoki-
netics of voriconazole. Safe adjustment of voriconazole dosages
requires a reasonable estimate of how and when nonlinear phar-
macokinetic behavior occurs in an individual patient, which is
governed by the Km-Vmax pair for that patient. Just as for clinical
trial data, it is not possible to estimate the extent of nonlinearity
until it is triggered or observed. One way this can be achieved is to
alter the rate of the initial infusion of voriconazole to try to capture
nonlinear behavior. This process is similar to stressing any dy-
namic system to observe and better understand the behavior of
that system. The second challenge is that the current software
needs a graphical user interface (GUI) to make it practical for
extensive use in clinical settings.We are currently working on this.
The third challenge is that the adaptive control problem using
differential equation solvers is computationally intensive, and
handheld devices, which are increasingly popular, are unlikely to
be adequate. A solution could be that a handheld device can be
used to access a larger computer and run the software remotely
(21). The fourth challenge is that the performance of the control-
ler in terms of its accuracy needs to be assessed in prospective
clinical trials. The fifth challenge is that the controller needs to be
tested for oral voriconazole therapy, whichmay be complicated by
high degrees of interoccasion and within-patient variability that
make Bayesian posterior estimation more difficult. Finally, the
sixth challenge relates to changing pharmacokinetics as a result of
physiological derangement or some other factor. The current
RightDose software for simple models contains an interacting
multiple-modelmethod to account for changing parameter values
over time within a single patient (see, for example, reference 22),
but this has not yet been implemented within the rightdose.exe
program described in this article.
In summary, the utility of this stochastic controller for vori-
conazole can now be further investigated, refined, and generalized
to other compounds. The development of software that can be
used individualize voriconazole therapy represents a natural pro-
gression from intensive pharmacokinetic studies and studies in
which concentration-effect relationships have been elucidated.
This controller offers promising potential for further improve-
ment in clinical outcomes for immunocompromised patients and
can be embedded within therapeutic drug monitoring strategies
for patients receiving voriconazole.
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